DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cancer Biomarkers Market - Forecast (2014-2021)" report to their offering.
Cancer biomarkers are biological molecule found in blood, other body fluids, or tissues and are indicative of the presence of cancer in the body. Cancer biomarkers improves the cancer detection and facilitate high speed, non-invasive diagnosis using genomics and proteomics based tools.
Globally, rising incidences of cancer, growing research on cancer biomarkers, and superior speed and accuracy of diagnosis are the prime growth drivers of global cancer biomarkers market. In addition, emerging economies such as China, India and others will create new opportunities for global cancer biomarkers market. However, higher capital investments, lack of reimbursement, and regulatory systems, and technical issues are the key restraints for global cancer biomarkers market.
Geographically North America dominated global cancer biomarkers market, followed by Europe due to growing government support for discovery and development of biomarkers, and rising usage of advanced omics technologies for the biomarker discovery. Asia Pacific is projected to have fastest growth, owing to rising incidences of cancer, and expansions by key market players in this region. Among all the applications, diagnostics segment has the highest market share in global cancer biomarkers market followed by drug discovery and development.
Companies Mentioned:
- Abbott Laboratories
- Affymetrix, Inc.
- Illumina, Inc.
- Qiagen N.V.
- Roche Diagnostics Ltd.
- Agilent Technologies, Inc.
- Quest Diagnostics Inc.
- Merck & Co. Inc.
- Hologic, Inc.
-
Becton, Dickinson and Company
Key Topics Covered:
1. Market Overview
2. Executive Summary
3. Market Landscape
4. Market Forces
5. Market, By Product
6. Market, By Type
7. Market, By Tumor Type
8. Market, By Technology
9. Market, By Application
10. Market, By Geography (2014-2021)
11. Cancer Biomarkers - Market Entropy
12. Company Profiles (Top 10 Companies)
13. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/jg5zn3/cancer_biomarkers
